By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
Panelists generally agree that Trulieve's current advantages are well-priced and may not sustain under full federal legalization. Tilray's international exposure and beverage diversification offer long-term growth opportunities.
Risk: Margin compression for Trulieve under federal legalization
Opportunity: Tilray's international exposure and beverage diversification
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Trulieve (OTC: TCNNF) last week saidthat it had received approval to list on the New York Stock Exchange (NYSE), making it the first U.S. cannabis company to be listed on a major exchange. It began trading on the NYSE under the ticker TRUL on June 10.
Its uplisting was made possible by the U.S. rescheduling of medical marijuana from a Schedule I to a Schedule III substance -- meaning it may have some medical benefits -- in April. After rescheduling, Trulieve made moves to consolidate its operations to consist solely of state-licensed medical marijuana facilities.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
The move is huge for the U.S. cannabis industry, but Canadian companies, such as Tilray (NASDAQ: TLRY), were already listed on U.S. major exchanges. Now that Trulieve and Tilray compete head-to-head on major exchanges, which is the better cannabis stock?
Tilray has an international presence, with operations in Canada, Europe, and, through its beverage interests, in the U.S.
Tilray is the No.2 Canadian cannabis company by market cap behind Cronos Group (NASDAQ: CRON), while Trulieve is the No. 2 U.S. company by market cap behind Curaleaf (OTC: CURLD). Although Trulieve has 240 dispensaries, Tilray operates strictly as a consumer packaged goods, cultivation, and wholesale manufacturing company.
Trulieve reported $100 million in adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) in its first quarter, while Tilray says it expects EBITDA to be between $62 million and $72 million this year.
Tilray reported revenue of $206.7 million in fiscal Q3 for the period ended Feb. 28, up 11%. That's not much less than Trulieve's $287 million in Q1 revenue, but Trulieve turned a profit, albeit a small one, with earnings per share (EPS) of $0.01. Tilray, on the other hand, had an EPS loss of $0.24.
Tilray's profit margins are dramatically narrower than Trulieve's. In the company's most recent earnings report, Trulieve boasted a robust gross profit margin of 59%, while Tilray's blended corporate gross margin was 27% and its cannabis-specific gross margin was 40%.
The gap stems from how price compression in their respective markets, the structure of their supply chains, and the strategic choices each company has made.
Tilray operates primarily as a wholesale licensed producer in Canada and Europe. In Canada, the market suffered from an acute oversupply of cultivation capacity after legalization. Too much weed chased too few consumers, triggering falling prices. Since legalization in 2018, prices for cannabis in Canada have steadily declined.
When retail prices drop due to competition, that squeezes wholesale manufacturers the hardest. Tilray is forced to lower its wholesale prices to remain competitive, but its fixed costs (large facility overhead, cultivation electricity, regulatory excise taxes) remain high.
Trulieve is a U.S. multistate operator (MSO) that functions as a vertically integrated retailer. Of the $1.2 billion in revenue Trulieve generated in 2025, roughly 93% came directly from its retail cash registers.
Trulieve owns the entire chain -- from the cultivation greenhouse to the processing lab to the actual retail counter -- so it captures the entire retail markup.
Falling prices have hit the U.S. market as well, but a vertically integrated retailer is more insulated from it. If the cost to produce a gram of flower drops from $1 to $0.50 due to manufacturing efficiencies, and the retail price slips slightly, Trulieve still retains a substantial margin cushion. It captures the consumer's final dollar, not a cut-rate wholesale price.
On top of that, Trulieve's core market has historically been Florida's limited-license medical structure, which acts as a regulatory moat, making prices much less volatile than in Canada's wide-open market.
Right now, Trulieve appears to be the fundamentally superior cannabis stock. While Tilray is a well-run company with great liquidity and a clever alcohol-hedge strategy, its core cannabis operations face lower margins and intense structural competition.
Trulieve, on the other hand, boasts an institutional-grade financial profile: better EBITDA margins, positive free cash flow, and profitability. With the U.S. adopting a Schedule III reclassification -- which directly relieves the exact 280E tax burdens that weighed down Trulieve's bottom line by preventing it from deducting many business operating expenses from taxable income -- Trulieve stands to capture the most immediate and profound financial upside.
Before you buy stock in Tilray Brands, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tilray Brands wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $442,220! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,230,114!
Now, it’s worth noting Stock Advisor’s total average return is 926% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 12, 2026. *
James Halley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cronos Group. The Motley Fool recommends Tilray Brands. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Regulatory timing and the realization of tax relief will be the decisive factors for outperformance, not current margin differentials alone."
The article pushes a Trulieve lead based on margins, profitability, and a NYSE uplisting, but that narrative hinges on regulatory timing that is uncertain. A Schedule III reclassification relief could take years to materialize in meaningful tax benefits, and ongoing capex plus compliance costs could pressure near-term cash flow. US MSO profitability remains tied to state-by-state licensing dynamics and competition. Tilray’s international exposure and potential margin upside from Canada/Europe price normalization offer a non-trivial upside path if demand stabilizes, meaning the TRUL vs TLRY comparison isn’t as clear-cut as the piece implies.
The NYSE uplisting may lift sentiment without delivering cash-flow gains; if US regulation stalls or Tilray cuts costs more aggressively, the relative advantage for Trulieve could narrow.
"The valuation gap between Trulieve and Tilray is less about operational superiority and more about the binary risk of U.S. federal policy versus the long-term, slow-burn global expansion of the cannabis market."
The article's enthusiasm for Trulieve (TCNNF) hinges on its vertical integration and the impact of Schedule III reclassification on 280E tax burdens. While the operational efficiency is clear, the article glosses over the extreme regulatory risk inherent in the U.S. cannabis market. If federal legalization or banking reform stalls, or if Florida’s ballot initiatives fail to expand the market, Trulieve’s 'moat' becomes a prison. Tilray (TLRY), meanwhile, is pivoting toward a diversified CPG (consumer packaged goods) model, specifically alcohol, which provides a hedge against cannabis price compression. Investors should view Trulieve as a high-beta play on U.S. policy, whereas Tilray is an M&A-driven bet on global legalization optionality.
Trulieve’s heavy reliance on the Florida medical market makes it dangerously vulnerable to a single state’s legislative shifts, whereas Tilray’s international footprint offers genuine, albeit slower, geographic diversification.
"Trulieve looks better *today* on profitability, but the article mistakes current market structure for permanent competitive advantage and ignores the tail risk of federal legalization destroying its pricing power."
The article's thesis—that Trulieve's vertical integration and U.S. market structure make it superior to Tilray—is structurally sound but ignores a critical timing risk. Trulieve's NYSE uplisting and Schedule III reclassification are priced in already; the stock has likely run. More importantly, the article assumes U.S. medical-only margins hold, but federal legalization (full Schedule I removal) would flood U.S. retail with competition, collapsing Trulieve's 59% gross margins toward Tilray's 40% within 18–24 months. Tilray's wholesale model, while currently margin-compressed, becomes less vulnerable in a fully legal U.S. market. The article also omits that Tilray holds meaningful European assets and a beverage hedge—optionality the piece dismisses too quickly.
If federal legalization accelerates (Democratic sweep in 2024, or bipartisan pressure post-rescheduling), Trulieve's regulatory moat evaporates and its 59% margins compress hard, while Tilray's diversified geography and wholesale scale become an asset, not a liability.
"Trulieve's Florida moat and retail model remain vulnerable to state policy shifts that the uplisting alone cannot neutralize."
The article correctly flags Trulieve's 59% gross margins and positive EPS versus Tilray's 27% blended margin and $0.24 loss, driven by vertical integration and Florida's limited-license protection. However, it underplays how Schedule III rescheduling still leaves 280E tax relief uncertain until IRS guidance and potential state-level tax hikes materialize. Trulieve's 93% retail revenue also exposes it to any slowdown in Florida patient growth or new license awards that erode its moat. Tilray's Canadian wholesale exposure is structurally weaker, yet its European footprint and beverage diversification offer optionality the piece dismisses too quickly.
Trulieve's NYSE listing and immediate 280E relief could trigger rapid multiple expansion before any regulatory reversal hits, leaving Tilray's international diversification looking like a slow-growth distraction.
"The margin-compression timeline is not as binary as claimed; moat durability could keep Trulieve’s margins higher longer, tempering downside versus Tilray."
Claude's timing risk is valid, but the '18–24 months to 40% margins' forecast is too binary. Real-world pricing, ongoing 280E relief, and Florida's moat may sustain mid-to-upper-50s margins for Trulieve even under partial legalization. The piece underweights moat durability and overweights a rapid margin collapse. Tilray's European footprint and beverages hedge remains supportive, but not a cure for Trulieve's longer-dated margin risk.
"Regulatory barriers to interstate commerce will sustain Trulieve's high margins well beyond the 24-month window suggested by Claude."
Claude, your margin compression thesis assumes a frictionless federal market, but you ignore the 'state-level barrier to entry' that persists post-legalization. Even if Schedule I is removed, interstate commerce remains a legal nightmare; local licensing and residency requirements will protect Trulieve’s margins far longer than 24 months. You are modeling a nationalized commodity market that doesn't exist yet, while ignoring that Tilray’s beverage pivot is a low-margin distraction that dilutes their core cannabis focus.
"Interstate commerce barriers are political theater, not durable moats—Trulieve's real edge is speed-to-market capital, which evaporates if federal legalization opens the floodgates to better-capitalized competitors."
Gemini's 'state-level barrier persists post-legalization' claim needs stress-testing. Interstate commerce restrictions are real, but they're political, not structural—and they erode fastest under full Schedule I removal when federal preemption arguments strengthen. Trulieve's moat isn't the licensing framework; it's the cash and operational scale to move first into newly legal states. That advantage compresses faster than Gemini suggests if capital flows to competitors post-rescheduling.
"Capital access post-uplisting accelerates M&A competition faster than state licensing friction can contain it."
Gemini overstates how long state barriers will shield Trulieve after rescheduling. Claude's point on capital flows matters here: NYSE uplisting plus 280E relief gives Trulieve and peers immediate firepower for out-of-state acquisitions, eroding Florida's limited-license advantage within 12-18 months even if interstate rules stay fragmented. Tilray's beverage cash flows could fund similar moves, turning geographic diversification into an active U.S. offensive tool rather than a passive hedge.
Panelists generally agree that Trulieve's current advantages are well-priced and may not sustain under full federal legalization. Tilray's international exposure and beverage diversification offer long-term growth opportunities.
Tilray's international exposure and beverage diversification
Margin compression for Trulieve under federal legalization